Sai Life Sciences Limited has announced the closure of its trading window from April 1, 2025, in compliance with SEBI’s Prohibition of Insider Trading Regulations, 2015, and the company’s Code of Conduct. The closure applies to all designated persons and their immediate relatives, prohibiting them from trading in the company’s securities until 48 hours after the declaration of the audited financial results for the quarter and financial year ending March 31, 2025.
The company has not yet announced the date of the board meeting for approving the financial results. Once the audited financials are finalized, the trading window will re-open, and all insiders will be informed.
Summary in Points: • Trading Window Closure Date: April 1, 2025
• Affected Personnel: Designated persons, immediate relatives, and insiders
• Duration of Closure: Until 48 hours after financial results are declared
• Financial Results: For the quarter and financial year ending March 31, 2025
• Board Meeting Date: To be announced later
Effect on Share Market: The trading window closure is a standard regulatory measure, and it is unlikely to have an immediate impact on Sai Life Sciences’ stock price. Investors may be waiting for the company’s financial results, which could drive activity in the stock once the window reopens.
Company Overview: Sai Life Sciences Limited is a leading contract research, development, and manufacturing organization (CRO-CDMO) that partners with pharmaceutical and biotechnology companies worldwide. Headquartered in Hyderabad, India, the company offers end-to-end solutions across the pharmaceutical value chain, including drug discovery, development, and commercial manufacturing.
📉 Stock Market Disclaimer
Disclaimer: This post is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy/sell any stock or share. Investing in the stock market involves risk. Past performance is not indicative of future results. Always conduct your own research or consult a licensed financial advisor before making investment decisions.
